相关实验视频
Updated: Jan 12, 2026

06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
37.3K
纠结和斑块:深入研究阿尔茨海默病的病理特征
Vanya1, Shilpa Kumari1, Kajal Bagri1
1Department of Pharmacology, Central University of Punjab, Bathinda, 151401 Punjab, India.
Neuroscience
|November 1, 2025
概括
阿尔茨海默病涉及粉样β和病理,导致认知能力下降. 了解这些复杂的机制是开发有效阿尔茨海默病治疗的关键.
科学领域:
- 神经科学是一个神经科学.
- 病理学 病理学 病理学
- 遗传学 遗传学 是一个
背景情况:
- 阿尔茨海默病 (AD) 是主要的神经退行性疾病,其特点是逐渐记忆和认知障碍.
- 阿尔茨海默症的病理生理学涉及粉样β (Aβ) 的过度生产/积累和的过酸化,导致神经元功能障碍.
- 遗传因素 (例如TREM2变体),衰老和生活方式影响AD的发病和进展.
研究的目的:
- 为提供阿尔茨海默病病理生理学的最新综合.
- 专注于关键机制,包括Aβ和tau病理,质激活和神经炎症.
- 突出需要对新型治疗策略有更深入的理解.
主要方法:
- 这是一个叙事评论.
- 它综合了关于AD病理生理学的当前知识.
- 专注于分子和细胞机制.
主要成果:
- 阿尔茨海默病涉及Aβ和tau的复杂相互作用,导致神经退行.
- 质细胞激活,神经炎症,神经发生障碍和血脑屏障功能障碍是关键组成部分.
- 目前的治疗方法主要是因为对疾病机制的不完全理解而管理症状.
结论:
- 对AD病理生理学的全面理解对于开发超越症状管理的有效治疗至关重要.
- 对Aβ和tau病理,神经炎症和其他机制的进一步研究至关重要.
- 需要改进干预措施,以应对阿尔茨海默病的全球流行率上升,并改善患者的治疗结果.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Amyloid Fibrils
11.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.6K
Amyloid Fibrils
6.3K
6.3K
Alzheimer's Disease: Treatment
801
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
801
Dementia
508
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
508
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K

